Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives-Reference-Cited by-同舟云学术

Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives

Published:2021-04-01 Issue:3 Volume:36 Page:237-251
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Lin Mai¹,Ta Robert T.¹,Kairemo Kalevi²³,Le Dao B.¹³,Ravizzini Gregory C.³

Affiliation:

1. Cyclotron Radiochemistry Facility, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

2. Department of Nuclear Medicine and Molecular Radiotherapy, Docrates Cancer Center, Helsinki, Finland.

3. Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2020.3603

Reference121 articles.

1. Cancer statistics, 2019

2. Impact of 68 Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis

3. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011

4. Trends in oncologic hybrid imaging

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation, Biological Evaluation, and First-in-Human Single-Photon Emission Computed Tomography (SPECT) Study of ^99mTc-Labeled Prostate-Specific Membrane Antigen (PSMA)-Targeted Radiotracers Containing Triazole with Reduced Kidneys Accumulation;ACS Pharmacology & Translational Science;2024-04-10

2. PARP Inhibitors: A New Horizon for Patients with Prostate Cancer;Biomedicines;2022-06-15

3. Radium-223 and Actinium-225 α-Emitter Radiopharmaceuticals in Treatment of Metastatic Castration-Resistant Prostate Cancer;Radiopharmaceuticals - Current Research for Better Diagnosis and Therapy;2022-06-15

4. PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?;Cancers;2022-02-11

5. Basis of Radiopharmaceutical Localization;The Pathophysiologic Basis of Nuclear Medicine;2022